[
  {
    "ts": null,
    "headline": "Moderna’s EU Backing For Combo Vaccine Shifts Respiratory Growth Focus",
    "summary": "Moderna, ticker NasdaqGS:MRNA, received a positive opinion from the European Medicines Agency’s CHMP for mCOMBRIAX, a combined COVID 19 and flu vaccine. The committee recommended mCOMBRIAX for marketing authorization in the European Union for adults aged 50 and above. This decision comes while Moderna faces ongoing regulatory scrutiny for its respiratory vaccines in the U.S. For you as an investor, this is a fresh development in Moderna’s efforts to expand its respiratory vaccine portfolio...",
    "url": "https://finnhub.io/api/news?id=90710f8e94fdfb519722e4b397323d4722da4262219b00fdc5f43bfd9f7214fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772262621,
      "headline": "Moderna’s EU Backing For Combo Vaccine Shifts Respiratory Growth Focus",
      "id": 139261024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna, ticker NasdaqGS:MRNA, received a positive opinion from the European Medicines Agency’s CHMP for mCOMBRIAX, a combined COVID 19 and flu vaccine. The committee recommended mCOMBRIAX for marketing authorization in the European Union for adults aged 50 and above. This decision comes while Moderna faces ongoing regulatory scrutiny for its respiratory vaccines in the U.S. For you as an investor, this is a fresh development in Moderna’s efforts to expand its respiratory vaccine portfolio...",
      "url": "https://finnhub.io/api/news?id=90710f8e94fdfb519722e4b397323d4722da4262219b00fdc5f43bfd9f7214fb"
    }
  }
]